A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2018-10-17
Target enrollment:
Participant gender:
Summary
The purpose of the Phase 1b portion of the study is to investigate how the body tolerates
necitumumab, in combination with gemcitabine and cisplatin chemotherapy as first line
treatment in participants with Stage IV squamous NSCLC and to determine the recommended dose
for the subsequent Phase 2 portion of the study.
The purpose of the Phase 2 portion of the study is to evaluate the efficacy of necitumumab in
combination with gemcitabine and cisplatin chemotherapy in participants with Stage IV
squamous NSCLC in a first-line setting.